Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Covington
Baxter
McKinsey
McKesson
US Department of Justice
Cipla
AstraZeneca

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,791,140

« Back to Dashboard

Which drugs does patent 8,791,140 protect, and when does it expire?

Patent 8,791,140 protects INLYTA and is included in one NDA.

This patent has twenty-five patent family members in twenty-one countries.
Summary for Patent: 8,791,140
Title:Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Inventor(s): Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/594,575
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,791,140

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,791,140

PCT Information
PCT FiledMarch 25, 2008PCT Application Number:PCT/IB2008/000792
PCT Publication Date:October 16, 2008PCT Publication Number: WO2008/122858

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Citi
Medtronic
Johnson and Johnson
Federal Trade Commission
Chubb
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.